Sederma launches anti-ageing ingredient for 60-plus
anti-ageing ingredient aimed at fortifying and restructuring the
thinning and fragile skin that tends to characterise the 60-plus
age category.
Essenskin is claimed to be a complementary source of calcium and essential amino acids, and is in turn designed to help rebuild the skin structure in an effort to reduce fine lines and wrinkles in key areas such a the neckline. Boosts skin metabolism According to Sederma the ingredient is especially designed to reboost cell metabolism and protein synthesis, rebalance ion flow and recreate calcium gradient in order to regulate the cell barrier's homeostasis and the epidermal differentiation. Sederma is tapping into one of the key trends in the industry - targeted personal care products aimed at the graying baby boomer generation. Marketers have targeted this group for its unprecedented spending power, which is also combined with a desire to maintain youthful and healthy looks. In vivo and in vitro testing The company said it has proved the efficacy of the ingredient through a series of in vitro and in vivo tests to determine the stimulation of the skin's metabolism. The test showed significant improvements in the skin's metabolism, demonstrating that cell multiplication increased by 213 per cent, while protein synthesis increased by 135 per cent. Likewise a test to determine how the ingredient protects skin cells from osmotic shock showed that cell viability increased by 454 per cent on average. Testing on sagging neck skin Meanwhile a two month in vivo test involving 29 female volunteers with a mean age of 60 years and mature and sagging neck skin also showed positive results after using a cream containing a 2.5 per cent dose of Essenskin. The tests showed that there was a visible improvement to the skin density, with 68 per cent of volunteers showing an improvement, while 80 per cent of the volunteers were said to have shown an improvement in skin elasticity and firmness. Final tests were also carried out on 100 panelists over a 21 day period, with the company reporting a confirmation of the in vivo test findings and a 'global satisfaction' for 20 different criteria.
